David Younger, CEO of A-Alpha Bio
David Younger is the Co-Founder and CEO of A-Alpha Bio, which provides high-throughput and quantitative characterization of protein-protein interactions for industry and academic applications. During his PhD, he worked with David Baker and Eric Klavins to develop synthetic biology tools that remove the experimental characterization bottleneck from the protein engineering pipeline. He is now focused on applying one such platform, called AlphaSeq, for the discovery and screening of small molecule drugs and biologics. David holds a BS in Bioengineering from Rice University and a PhD in Bioengineering from the University of Washington.